Incannex doses first patient in Phase 2 DReAMzz trial of IHL-42X for sleep apnea
IXHL•Prior results and development path
- Earlier Phase 2 RePOSA results have already been presented, showing meaningful improvement versus placebo with a favorable safety profile.
- DReAMzz aims to refine the treatment regimen and support dose selection for a planned Phase 3 program.
- FDA Fast Track status strengthens the regulatory path and could speed development timelines for IHL-42X.
First patient dosed in Phase 2 DReAMzz study
Incannex dosed the first patient in its DReAMzz Phase 2 study of IHL-42X for obstructive sleep apnea.
